Related Experiment Video

Updated: Mar 26, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.8K

G protein-coupled receptors as targets for anti-diabetic therapeutics

Da Young Oh1, Jerrold M Olefsky1

  • 1Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California 92093, USA.

Nature Reviews. Drug Discovery
|January 30, 2016
PubMed

Insights

Obesity and type 2 diabetes (T2D) are rising globally. Targeting G protein-coupled receptors (GPCRs) in metabolic tissues offers a promising avenue for developing new anti-diabetic drugs to improve T2D treatment outcomes.

Area of Science:

  • Metabolic disorders
  • Endocrinology
  • Pharmacology

Background:

  • Rising global prevalence of obesity and type 2 diabetes (T2D).
  • Limited long-term success of lifestyle modifications for weight management in T2D patients.
  • Need for safe and effective pharmacological interventions for T2D treatment.

Purpose of the Study:

  • To explore the potential of G protein-coupled receptors (GPCRs) as therapeutic targets for T2D.
  • To review current and future anti-diabetic drug discovery strategies focusing on GPCRs.

Main Methods:

  • Literature review and analysis of GPCRs in metabolic tissues.
  • Discussion of GPCRs' role in adipose tissue, liver, muscle, pancreatic islets, immune cells, and the central nervous system.
  • Focus on GPCRs as targets for novel anti-diabetic compounds.

Main Results:

  • GPCRs represent a key target class for anti-diabetic drug development.
  • Targeting GPCRs in various metabolic tissues holds significant therapeutic potential.
  • GPCR-based therapies could offer new solutions for T2D management.

Conclusions:

  • GPCRs are crucial targets for developing innovative T2D treatments.
  • Further research into GPCR modulation can lead to effective anti-diabetic medications.
  • Targeting GPCRs is a promising strategy to address the growing T2D epidemic.

More Related Videos

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination12:33

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

66.3K
An In Ovo Model for Testing Insulin-mimetic Compounds06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.2K

Related Concept Videos

G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
19.5K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

2.4K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.8K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
919
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K